Insider purchase
Processa Pharmaceuticals (NASDAQ:PCSA) reported that Chief Executive Officer George K Ng acquired 2,136 shares of common stock on March 31, 2026. The shares were purchased at $2.535 each, bringing the total cost of the transaction to $5,414.
Ownership after the trade
Following this purchase, Mr. Ng directly holds 3,649 shares of Processa Pharmaceuticals. In addition to his direct ownership, he has indirect holdings of 3,488 shares listed as George Ng IRRA FOB George Ng, and another 800 shares held through the Ng Cha Family Trust.
Market context and valuation
The stock has gained 9.78% over the last week but remains down 75% over the past year. According to InvestingPro analysis, PCSA is trading close to its Fair Value of $2.63. InvestingPro also records that the company has a market capitalization of $6.97 million and reports that the balance sheet shows more cash than debt. The InvestingPro service provides 11 additional ProTips for investors tracking PCSA.
Clinical update
In operational news, Processa Pharmaceuticals has finished enrolling and dosing 20 patients that will be included in an interim analysis of its Phase 2 clinical trial for NGC-Cap in advanced or metastatic breast cancer. The investigational regimen NGC-Cap combines PCS6422 with capecitabine and is being evaluated against the current standard of capecitabine alone.
The trial cohort enrolled patients who previously received at least one cancer treatment, with the median number of prior therapies reported as between two and three regimens. Completion of dosing for these 20 patients enables the planned interim analysis to proceed, a step the company describes as a milestone in the study timeline.
What this means for investors and stakeholders
The insider purchase, modest in dollar terms, increases the CEO’s direct and indirect exposure to PCSA alongside a clinical progress update that advances a Phase 2 program to its interim review. The market capitalization, cash position relative to debt, and InvestingPro valuation and tips are highlighted as context investors may use when assessing the company.
Note on scope
All figures, ownership details, and clinical trial information above are drawn from the company’s reported transaction and InvestingPro analysis.